01—Abstract
Summary
Summary of the 10-Q filed August 5, 2024. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. reported strong financial results for the quarter and six months ended June 30, 2024.
Sales increased by 7% to $16.1 billiona in the second quarter and 8% to $31.9 billion year-to-date, driven primarily by growth in the oncology and vaccines segments, particularly from Keytruda and Gardasil/Gardasil 9. Net income attributable to Merck & Co., Inc. significantly improved to $5.5 billion ($2.15 per share) in the second quarter, compared to a net loss of $6.0 billion ($2.35 per share) in the prior year period. This turnaround is largely due to the absence of substantial acquisition-related charges that impacted the prior year.
The company continued its strategic growth through significant business development, including the acquisition of Elanco's aqua business and EyeBio in July 2024, and Harpoon Therapeutics in March 2024. These investments, while impacting R&D expenses, are positioned to bolster the company's pipeline and future growth.
Merck also announced a new $4.0 billionb restructuring program aimed at optimizing its manufacturing network, expected to yield substantial annual cost savings by 2031. The company's liquidity remains strong, with robust operating cash flow supporting its strategic initiatives and shareholder returns, including dividends and share repurchases.
02—Key points
Key Highlights
- Sales increased 7% to $16.1 billion in Q2 2024 and 8% to $31.9 billion year-to-date, driven by Keytruda and Gardasil/Gardasil 9.
- Net income attributable to Merck & Co., Inc. was $5.5 billion ($2.15 per share) in Q2 2024, a significant improvement from a net loss of $6.0 billion ($2.35 per share) in Q2 2023, primarily due to the absence of large acquisition charges.
- Research and Development (R&D) expenses decreased significantly to $3.5 billion in Q2 2024 from $13.3 billion in Q2 2023, mainly due to the absence of the $10.2 billion charge for the Prometheus acquisition in the prior year.
- The company made substantial business development moves in Q3 2024 with the acquisition of Elanco's aqua business and EyeBio, and in Q1 2024 with the acquisition of Harpoon Therapeutics, indicating continued investment in pipeline expansion.
- Merck initiated a new $4.0 billion restructuring program in January 2024 to optimize its manufacturing network, expected to generate approximately $750 million in annual net cost savings by 2031.
- Operating cash flow remains strong, providing $8.7 billion in the first six months of 2024, supporting investments in business development, capital expenditures, and shareholder returns.
- The company is facing ongoing pricing pressures and regulatory scrutiny, particularly related to the Inflation Reduction Act (IRA) and its impact on Januvia, with a lawsuit filed against the U.S. government.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 5, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $16.11B$15.04B | +7.2% |
| Cost of Revenue | $3.75B$4.02B | −6.9% |
| Gross Profit | $12.37B$11.01B | +12.3% |
| R&D Expenses | $3.50B$13.32B | −73.7% |
| SG&A Expenses | $2.74B$2.70B | +1.4% |
| Net Income | $5.46B-$5.97B | +191.3% |
| EPS (Basic) | $2.15$-2.35 | +191.5% |
| EPS (Diluted) | $2.14$-2.35 | +191.1% |
| Shares Outstanding (Basic) | 2.53B2.54B | −0.2% |
| Shares Outstanding (Diluted) | 2.54B2.54B | +0.2% |
05—Questions
Frequently Asked Questions
What drove the significant increase in Net Income for Q2 2024 compared to Q2 2023?
The substantial increase in net income for Q2 2024 (from a net loss in Q2 2023) is primarily attributable to the absence of significant acquisition-related charges that were recorded in the prior year. Specifically, the $10.2 billion charge for the acquisition of Prometheus Biosciences in Q2 2023 heavily impacted the previous year's results. The current quarter's results benefited from strong sales growth and a more favorable cost structure.
How are Merck's recent acquisitions impacting R&D expenses?
Merck has been actively pursuing strategic acquisitions. The acquisition of Harpoon Therapeutics in March 2024 resulted in a $656 million charge to R&D expenses in the first six months of 2024. While recent acquisitions like Elanco's aqua business and EyeBio (in July 2024) will impact future R&D and operational expenses, the reported R&D expenses for Q2 2024 and year-to-date 2024 show a significant decrease compared to the prior year, largely because the large Prometheus acquisition-related charge is no longer present.
What is the impact of the Inflation Reduction Act (IRA) on Merck's business?
The IRA is impacting Merck's business through several mechanisms. Januvia was selected for the first year of the IRA's 'Drug Price Negotiation Program,' leading to government price-setting effective January 1, 2026. Merck has filed a lawsuit challenging this program. Additionally, the IRA's redesign of Medicare Part D and potential penalties for price increases above inflation are ongoing concerns. These factors, combined with global healthcare cost containment efforts, are expected to negatively affect sales and profits.
What is the status of the Keytruda litigation with Johns Hopkins University (JHU)?
Merck is involved in litigation with JHU concerning patents related to Keytruda. Merck alleges JHU breached a collaboration agreement by filing and licensing patents without Merck's involvement. JHU has counterclaimed for willful infringement. Merck has filed inter partes review (IPR) petitions challenging the validity of JHU's patents, and the District Court has stayed the case pending the outcome of the PTAB proceedings.
06—Continue